Novel therapeutic targets in chordoma

Mohamad Bydon, Kyriakos Papadimitriou, Timothy Witham, Jean Paul Wolinsky, Ali Bydon, Daniel Sciubba, Ziya Gokaslan

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Introduction: Chordomas are malignant bone tumors arising from notochordal remnants. They most commonly occur at the sacrum, skull base, and spine. The gold standard treatment for these tumors is a combination of en-bloc resection and radiation therapy. Areas covered: Recent genomic studies have identified duplication of the gene brachyury as a major susceptibility mutation in familial chordomas. Studies on sporadic chordomas have identified several tumor markers, using microRNAs and Comparative Genome Hybridization. In this article, we highlight current advances in research on the molecular characterization of chordomas. Expert opinion: Scientific advances have allowed for the identification of numerous tumor markers involved in chordoma pathogenesis. In the future, chordoma cell lines will be produced that silence or over-express these tumor markers. As we increase our understanding of the mechanism of chordoma tumor proliferation, we can expect the development of targeted drug therapies.

Original languageEnglish (US)
Pages (from-to)1139-1143
Number of pages5
JournalExpert Opinion on Therapeutic Targets
Volume16
Issue number11
DOIs
StatePublished - Nov 2012
Externally publishedYes

Fingerprint

Chordoma
Tumor Biomarkers
Tumors
Genes
Drug therapy
Radiotherapy
MicroRNAs
Bone
Therapeutics
Cells
Sacrum
Neoplasms
Gene Duplication
Comparative Genomic Hybridization
Skull Base
Expert Testimony
Spine
Bone and Bones
Drug Therapy
Cell Line

Keywords

  • Brachyury
  • CDKN2A
  • Chordoma
  • Imatinib
  • JHC7 chordoma cell line
  • Met
  • PTEN

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Bydon, M., Papadimitriou, K., Witham, T., Wolinsky, J. P., Bydon, A., Sciubba, D., & Gokaslan, Z. (2012). Novel therapeutic targets in chordoma. Expert Opinion on Therapeutic Targets, 16(11), 1139-1143. https://doi.org/10.1517/14728222.2012.714772

Novel therapeutic targets in chordoma. / Bydon, Mohamad; Papadimitriou, Kyriakos; Witham, Timothy; Wolinsky, Jean Paul; Bydon, Ali; Sciubba, Daniel; Gokaslan, Ziya.

In: Expert Opinion on Therapeutic Targets, Vol. 16, No. 11, 11.2012, p. 1139-1143.

Research output: Contribution to journalReview article

Bydon, M, Papadimitriou, K, Witham, T, Wolinsky, JP, Bydon, A, Sciubba, D & Gokaslan, Z 2012, 'Novel therapeutic targets in chordoma', Expert Opinion on Therapeutic Targets, vol. 16, no. 11, pp. 1139-1143. https://doi.org/10.1517/14728222.2012.714772
Bydon M, Papadimitriou K, Witham T, Wolinsky JP, Bydon A, Sciubba D et al. Novel therapeutic targets in chordoma. Expert Opinion on Therapeutic Targets. 2012 Nov;16(11):1139-1143. https://doi.org/10.1517/14728222.2012.714772
Bydon, Mohamad ; Papadimitriou, Kyriakos ; Witham, Timothy ; Wolinsky, Jean Paul ; Bydon, Ali ; Sciubba, Daniel ; Gokaslan, Ziya. / Novel therapeutic targets in chordoma. In: Expert Opinion on Therapeutic Targets. 2012 ; Vol. 16, No. 11. pp. 1139-1143.
@article{0ebd247eff1647c5b7370ed32cdb61e3,
title = "Novel therapeutic targets in chordoma",
abstract = "Introduction: Chordomas are malignant bone tumors arising from notochordal remnants. They most commonly occur at the sacrum, skull base, and spine. The gold standard treatment for these tumors is a combination of en-bloc resection and radiation therapy. Areas covered: Recent genomic studies have identified duplication of the gene brachyury as a major susceptibility mutation in familial chordomas. Studies on sporadic chordomas have identified several tumor markers, using microRNAs and Comparative Genome Hybridization. In this article, we highlight current advances in research on the molecular characterization of chordomas. Expert opinion: Scientific advances have allowed for the identification of numerous tumor markers involved in chordoma pathogenesis. In the future, chordoma cell lines will be produced that silence or over-express these tumor markers. As we increase our understanding of the mechanism of chordoma tumor proliferation, we can expect the development of targeted drug therapies.",
keywords = "Brachyury, CDKN2A, Chordoma, Imatinib, JHC7 chordoma cell line, Met, PTEN",
author = "Mohamad Bydon and Kyriakos Papadimitriou and Timothy Witham and Wolinsky, {Jean Paul} and Ali Bydon and Daniel Sciubba and Ziya Gokaslan",
year = "2012",
month = "11",
doi = "10.1517/14728222.2012.714772",
language = "English (US)",
volume = "16",
pages = "1139--1143",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Novel therapeutic targets in chordoma

AU - Bydon, Mohamad

AU - Papadimitriou, Kyriakos

AU - Witham, Timothy

AU - Wolinsky, Jean Paul

AU - Bydon, Ali

AU - Sciubba, Daniel

AU - Gokaslan, Ziya

PY - 2012/11

Y1 - 2012/11

N2 - Introduction: Chordomas are malignant bone tumors arising from notochordal remnants. They most commonly occur at the sacrum, skull base, and spine. The gold standard treatment for these tumors is a combination of en-bloc resection and radiation therapy. Areas covered: Recent genomic studies have identified duplication of the gene brachyury as a major susceptibility mutation in familial chordomas. Studies on sporadic chordomas have identified several tumor markers, using microRNAs and Comparative Genome Hybridization. In this article, we highlight current advances in research on the molecular characterization of chordomas. Expert opinion: Scientific advances have allowed for the identification of numerous tumor markers involved in chordoma pathogenesis. In the future, chordoma cell lines will be produced that silence or over-express these tumor markers. As we increase our understanding of the mechanism of chordoma tumor proliferation, we can expect the development of targeted drug therapies.

AB - Introduction: Chordomas are malignant bone tumors arising from notochordal remnants. They most commonly occur at the sacrum, skull base, and spine. The gold standard treatment for these tumors is a combination of en-bloc resection and radiation therapy. Areas covered: Recent genomic studies have identified duplication of the gene brachyury as a major susceptibility mutation in familial chordomas. Studies on sporadic chordomas have identified several tumor markers, using microRNAs and Comparative Genome Hybridization. In this article, we highlight current advances in research on the molecular characterization of chordomas. Expert opinion: Scientific advances have allowed for the identification of numerous tumor markers involved in chordoma pathogenesis. In the future, chordoma cell lines will be produced that silence or over-express these tumor markers. As we increase our understanding of the mechanism of chordoma tumor proliferation, we can expect the development of targeted drug therapies.

KW - Brachyury

KW - CDKN2A

KW - Chordoma

KW - Imatinib

KW - JHC7 chordoma cell line

KW - Met

KW - PTEN

UR - http://www.scopus.com/inward/record.url?scp=84867491814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867491814&partnerID=8YFLogxK

U2 - 10.1517/14728222.2012.714772

DO - 10.1517/14728222.2012.714772

M3 - Review article

C2 - 22860993

AN - SCOPUS:84867491814

VL - 16

SP - 1139

EP - 1143

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 11

ER -